What is FOXO4-DRI? What it does, benefits and what the evidence shows

FOXO4-DRI is a synthetic peptide designed to make senescent cells, the aged, non-dividing cells that linger in tissues, die by apoptosis while leaving healthy cells alone. It was described in a 2017 paper in Cell and is studied only in mice and cell cultures. We found no human trial, no approval and no listing in the US drug databases we searched. The "reverse aging" claims that sell it have nothing behind them in people.

What FOXO4-DRI is and how it works

Senescent cells stop dividing but do not die. They stay put and release inflammatory signals, and researchers suspect they contribute to age-related decline. The 2017 Cell paper asked how senescent cells avoid dying and identified a protein called FOXO4 as a pivot in their survival. The team designed a FOXO4 peptide that interferes with the way FOXO4 binds p53, a protein that can trigger cell death. In senescent cells this pushed p53 out of the nucleus and set off apoptosis (Baar et al., Cell, 2017).

The name describes the design. In FOXO4-DRI (D-retro-inverso isoform), the natural L-amino acids are replaced with D-amino acids that mimic the part of FOXO4 that binds p53 (Kong et al., Communications Biology, 2025). A structural study in 2025 showed the peptide binds a region of p53 and that a positively charged cell-entry segment of the peptide contributes to that binding (Bourgeois et al., Nature Communications, 2025).

Drugs that kill senescent cells are called senolytics. The best-known human senolytic work used small-molecule drugs, not this peptide, and consists of small pilot studies, for example an open-label study of 14 people with idiopathic pulmonary fibrosis (Justice et al., EBioMedicine, 2019). FOXO4-DRI has not reached that stage.

What people use it for

What the research actually shows

The original mouse study

The 2017 paper is the foundation for almost everything else. The authors report that under conditions where the peptide was well tolerated in mice, it neutralized the toxic effects of the chemotherapy drug doxorubicin. In a fast-aging mouse strain and in naturally aged mice, it restored fitness, fur density and kidney function (Baar et al., Cell, 2017). The abstract describes a mechanism (p53 nuclear exclusion and apoptosis in senescent cells) and functional outcomes in mice. It is a preclinical study, and its own conclusion is that targeting senescent cells "is feasible", not that it works in people.

Follow-up mouse and cell studies

Later work has mostly come from different groups applying the peptide to specific tissues, again in animals or cells.

• Testes. In naturally aged mice, the peptide targeted senescent Leydig cells (the testosterone-producing cells) and eased an age-related fall in testosterone secretion, and a second study reported better sperm quality in aged mice (Zhang et al., 2020; Li et al., 2024). The evidence is two mouse studies.
• Lung. In mice with bleomycin-induced lung fibrosis, the peptide reduced senescent cells and collagen deposition, and the authors compared its effect with the approved drug pirfenidone (Han et al., 2022). A second mouse study reported milder scarring (Liu et al., 2023). Another group found that in a lung cancer model it made tumor cells more sensitive to radiation and reduced radiation-induced lung scarring (Meng et al., JCI Insight, 2021).
• Blood vessels. In naturally aged and accelerated-aging mice, treatment improved aortic function and reduced markers of vascular aging (Hu et al., 2025).
• Human cells in culture. In cartilage cells taken from healthy donors and expanded in the lab, the peptide removed more than half of the late-stage senescent cells but did not improve cartilage formation, and the authors said its usefulness needed more work (Huang et al., 2021). In keloid tissue cultures and fibroblasts it promoted cell death, and the authors describe potential as a treatment, not a demonstrated one (Kong et al., 2025).

Two honest observations. Most of these are single studies in one mouse model, and they cluster around one mechanism, so agreement between them is not the same as independent replication of a human benefit. And nobody has run a human trial: a ClinicalTrials.gov search for the peptide's name returned no studies when we checked on September 29, 2026.

Human data

There is none for FOXO4-DRI itself. No study we found gives it to people, measures senescent cells in people, or reports human safety. The only human tissue evidence is cultured cells, above.

Side effects and risks

• Unknown in humans. No human safety data exists. Everything below is from animals and theory.
• A mouse study found harm. In a 2023 Circulation study, removing senescent cells worsened pulmonary hypertension in several mouse and rat models. That included a genetic method and the drug ABT263, and in one mouse model it included FOXO4-DRI, which was associated with worse lung blood-vessel pressures and loss of lung endothelial cells (Born et al., Circulation, 2023). The authors say senolytic strategies may need consideration for their effects on pulmonary vessels.
• Senescent cells are not purely harmful. In mice, senescent cells appeared early after a skin wound and sped up wound closure through a growth factor they secrete (Demaria et al., Developmental Cell, 2014). That study removed senescent cells genetically, not with FOXO4-DRI, so it shows a principle, not a FOXO4-DRI side effect. Nobody knows whether clearing them in an older person would help or hurt healing.
• What "well tolerated" means. The 2017 paper's wording is "well tolerated in vivo" under the conditions used (Baar et al., 2017). Tolerance in mice does not establish tolerance in people.
• Regulatory status. We found no approved product: a drug-name search of DailyMed and a search of the openFDA Drugs@FDA database returned nothing for FOXO4-DRI or FOXO4, and it does not appear on FDA's page of bulk drug substances with significant safety risks (FDA, page current as of April 22, 2026). We did not search other regulators. Absence from a list means no one has evaluated it there, not that it is safe.

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for FOXO4-DRI that we can count yet. That doesn't mean vials are good or bad; it means we can't say. If you have had a vial tested, submitting the report is the fastest way to change that.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, lean on the general checks. Look at each vendor's full record and how many reports sit behind the score, and treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). FOXO4-DRI is a modified peptide with no track record in our data, so an independent identity and purity test on your own vial is worth paying for; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Readers interested in aging biology also look at epitalon, NAD+ and the mitochondrial peptide humanin; the peptide hub lists every compound we track.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; FOXO4-DRI has no approval anywhere we searched and no human trial we could find.